Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 860.24 Thousand USD | -18.81% |
| 2022 | 1.05 Million USD | 5.52% |
| 2021 | 1 Million USD | 27.39% |
| 2020 | 788.26 Thousand USD | -17.48% |
| 2019 | 955.21 Thousand USD | 98.23% |
| 2018 | 481.87 Thousand USD | 5.53% |
| 2017 | 456.63 Thousand USD | 66.02% |
| 2016 | 275.04 Thousand USD | 41.9% |
| 2015 | 193.82 Thousand USD | 615.07% |
| 2014 | 27.1 Thousand USD | -88.08% |
| 2013 | 227.48 Thousand USD | 4639.75% |
| 2012 | -5011.00 USD | -100.17% |
| 2011 | 2.91 Million USD | 29023.15% |
| 2010 | 9999.00 USD | 1000000.0% |
| 2009 | -1.00 USD | -100.02% |
| 2008 | 6429.00 USD | 111.95% |
| 2007 | -53.79 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 873.18 Thousand USD | 1.5% |
| 2024 Q2 | 953.18 Thousand USD | 9.16% |
| 2023 FY | 860.24 Thousand USD | -18.81% |
| 2023 Q4 | 860.24 Thousand USD | 7.65% |
| 2023 Q1 | 1.19 Million USD | 12.81% |
| 2023 Q2 | 771.28 Thousand USD | -35.47% |
| 2023 Q3 | 799.13 Thousand USD | 3.61% |
| 2022 Q2 | 905.51 Thousand USD | -5.13% |
| 2022 Q3 | 998.31 Thousand USD | 10.25% |
| 2022 Q4 | 1.05 Million USD | 6.14% |
| 2022 Q1 | 954.52 Thousand USD | -4.94% |
| 2022 FY | 1.05 Million USD | 5.52% |
| 2021 Q3 | 1.06 Million USD | 6.26% |
| 2021 FY | 1 Million USD | 27.39% |
| 2021 Q2 | 1 Million USD | -2.42% |
| 2021 Q4 | 1 Million USD | -5.59% |
| 2021 Q1 | 1.02 Million USD | 30.14% |
| 2020 Q3 | 749.89 Thousand USD | -26.24% |
| 2020 Q4 | 788.26 Thousand USD | 5.12% |
| 2020 Q1 | 1.07 Million USD | 12.96% |
| 2020 FY | 788.26 Thousand USD | -17.48% |
| 2020 Q2 | 1.01 Million USD | -5.78% |
| 2019 Q1 | 552.37 Thousand USD | 14.63% |
| 2019 Q4 | 955.21 Thousand USD | 86.88% |
| 2019 Q2 | 554.69 Thousand USD | 0.42% |
| 2019 Q3 | 511.12 Thousand USD | -7.85% |
| 2019 FY | 955.21 Thousand USD | 98.23% |
| 2018 Q2 | 420.23 Thousand USD | -9.03% |
| 2018 Q3 | 471.42 Thousand USD | 12.18% |
| 2018 Q4 | 481.87 Thousand USD | 2.22% |
| 2018 FY | 481.87 Thousand USD | 5.53% |
| 2018 Q1 | 461.93 Thousand USD | 1.16% |
| 2017 Q3 | 418.87 Thousand USD | 2.67% |
| 2017 Q4 | 456.63 Thousand USD | 9.01% |
| 2017 FY | 456.63 Thousand USD | 66.02% |
| 2017 Q2 | 407.99 Thousand USD | 37.88% |
| 2017 Q1 | 295.9 Thousand USD | 7.59% |
| 2016 Q4 | 275.04 Thousand USD | 79.25% |
| 2016 Q3 | 153.43 Thousand USD | 68.83% |
| 2016 Q1 | -34.4 Thousand USD | -117.39% |
| 2016 FY | 275.04 Thousand USD | 41.9% |
| 2016 Q2 | 90.88 Thousand USD | 364.12% |
| 2015 FY | 193.82 Thousand USD | 615.07% |
| 2015 Q4 | 197.81 Thousand USD | 819.87% |
| 2015 Q3 | 21.5 Thousand USD | 394.99% |
| 2015 Q2 | -7290.00 USD | 59.65% |
| 2015 Q1 | -18.06 Thousand USD | -166.66% |
| 2014 Q2 | 227.13 Thousand USD | 2.15% |
| 2014 Q1 | 222.36 Thousand USD | -2.25% |
| 2014 FY | 27.1 Thousand USD | -88.08% |
| 2014 Q4 | 27.1 Thousand USD | 8587.82% |
| 2014 Q3 | 312.00 USD | -99.86% |
| 2013 Q2 | 224.29 Thousand USD | 221.23% |
| 2013 Q4 | 227.48 Thousand USD | -4.1% |
| 2013 Q1 | 69.82 Thousand USD | 1493.41% |
| 2013 FY | 227.48 Thousand USD | 4639.75% |
| 2013 Q3 | 237.21 Thousand USD | 5.76% |
| 2012 Q1 | 2.88 Million USD | -0.9% |
| 2012 Q3 | 78.43 Thousand USD | -97.47% |
| 2012 Q4 | -5011.00 USD | -106.39% |
| 2012 FY | -5011.00 USD | -100.17% |
| 2012 Q2 | 3.09 Million USD | 7.22% |
| 2011 Q2 | 3.02 Million USD | 5092.06% |
| 2011 FY | 2.91 Million USD | 29023.15% |
| 2011 Q4 | 2.91 Million USD | -1.85% |
| 2011 Q1 | 58.27 Thousand USD | 482.76% |
| 2011 Q3 | 2.96 Million USD | -1.93% |
| 2010 Q3 | 19.99 Thousand USD | 2000000.0% |
| 2010 Q4 | 9999.00 USD | -50.0% |
| 2010 Q1 | -1.00 USD | 0.0% |
| 2010 FY | 9999.00 USD | 1000000.0% |
| 2010 Q2 | -1.00 USD | 0.0% |
| 2009 Q3 | 9999.00 USD | 47.07% |
| 2009 Q4 | -1.00 USD | -100.01% |
| 2009 Q2 | 6799.00 USD | 5.76% |
| 2009 Q1 | 6429.00 USD | 0.0% |
| 2009 FY | -1.00 USD | -100.02% |
| 2008 Q4 | 6429.00 USD | 8672.0% |
| 2008 FY | 6429.00 USD | 111.95% |
| 2008 Q2 | -375.00 USD | 99.17% |
| 2008 Q3 | -75.00 USD | 80.0% |
| 2008 Q1 | -45.32 Thousand USD | 15.75% |
| 2007 FY | -53.79 Thousand USD | 0.0% |
| 2007 Q4 | -53.79 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 65767.252% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 84.77% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.99% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 444.62% |
| Rebus Holdings, Inc. | 305 Thousand USD | -182.046% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 113.645% |
| Qrons Inc. | 351.42 Thousand USD | -144.785% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -38.222% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 98.019% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 4315.215% |
| Skye Bioscience, Inc. | -5.72 Million USD | 115.036% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 94.543% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 79.11% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -114.071% |
| SQZ Biotechnologies Company | -36.23 Million USD | 102.374% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 61.635% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 7.22% |
| Mesoblast Limited | 55.85 Million USD | 98.46% |
| Marizyme, Inc. | 18.56 Million USD | 95.367% |
| Genus plc | 190.6 Million USD | 99.549% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 61.525% |
| Pharming Group N.V. | 109.8 Million USD | 99.217% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 29.133% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -26.506% |
| ContraFect Corporation | -6.02 Million USD | 114.275% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -538.924% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 25.548% |
| IMV Inc. | 7.67 Million USD | 88.785% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 84.365% |
| MultiCell Technologies, Inc. | 90.04 USD | -955298.712% |
| ONE Bio Corp. | 9.04 Million USD | 90.484% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 217.203% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 93.355% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 37.116% |
| Q BioMed Inc. | 4.06 Million USD | 78.812% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 97.185% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 14.635% |
| Biomind Labs Inc. | 711.4 Thousand USD | -20.922% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.579% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 56.975% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 93.283% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -139.148% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -515.319% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -4229.999% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 60.933% |
| GB Sciences, Inc. | 1.74 Million USD | 50.768% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 568.062% |
| HST Global, Inc. | 96.79 Thousand USD | -788.743% |
| CSL Limited | 10.52 Billion USD | 99.992% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -317.153% |
| Halberd Corporation | 144.72 Thousand USD | -494.413% |
| Enzolytics Inc. | 981.65 Thousand USD | 12.368% |
| Agentix Corp. | 37.63 Thousand USD | -2185.99% |
| Resverlogix Corp. | 6.45 Million USD | 86.665% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 227.805% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.042% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 101.83% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 87.834% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 68.241% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 109.731% |
| AVAX Technologies, Inc. | -5.9 Million USD | 114.572% |
| Zenith Capital Corp. | 10.06 Thousand USD | -8447.705% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.081% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -329.193% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 63.947% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -422.914% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 4796.151% |
| Kadimastem Ltd | -253.1 Thousand USD | 439.879% |
| Helix BioMedix, Inc. | -2.57 Million USD | 133.472% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 95.757% |
| BioStem Technologies, Inc. | 4.47 Million USD | 80.764% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -327.44% |
| LadRx Corporation | -2.03 Million USD | 142.242% |
| Cell Source, Inc. | 9.23 Million USD | 90.682% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -35.435% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -35.435% |
| NovAccess Global Inc. | 2.17 Million USD | 60.512% |
| Affymax, Inc. | -5.59 Million USD | 115.37% |
| Itoco Inc. | 228.3 Thousand USD | -276.795% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -532.581% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 82.646% |
| Mobile Lads Corp. | 484.23 Thousand USD | -77.651% |
| CytoDyn Inc. | 20.26 Million USD | 95.754% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 133058.423% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 9381.5% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 88.837% |
| SYBLEU INC | 473.71 Thousand USD | -81.595% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 80.699% |
| International Stem Cell Corporation | 2.59 Million USD | 66.786% |
| Bioxytran, Inc. | 1.89 Million USD | 54.698% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1278.304% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 60.556% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 74.949% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 89.942% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -11.343% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 168.819% |
| Neutra Corp. | 52.18 Thousand USD | -1548.382% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 134.562% |
| PureTech Health plc | -167.19 Million USD | 100.515% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 451.251% |
| IXICO plc | -4.44 Million USD | 119.355% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 93.492% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.432% |
| CSL Limited | 10.52 Billion USD | 99.992% |
| Cellectis S.A. | -43.81 Million USD | 101.963% |